Latest From Cathy Kelly
Regeneron and Eli Lilly have seen limited uptake for their COVID treatments; CMS payment increase addresses concerns that inadequate reimbursement has hampered use of the monoclonal antibody drugs.
Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.
Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.
First-of-its-kind state law requires 100% of rebates be redirected to offset patient cost sharing at the point of sale in commercial insurance plans.
Accelerated Approvals Could Have Expiration Dates, Annual Reviews To Promote Confirmatory Trials, ICER Suggests
Institute for Clinical and Economic Review tackles reform of US FDA’s accelerated approval program in white paper responding to payer concerns about managing high-cost drugs supported by limited efficacy data and patient frustrations over possible access restrictions.
US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost
HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.